Mylan Laboratories Limited v. Food and Drug Administration

How courts have described this case

Verbatim parenthetical descriptions written by other courts when citing this decision. Ranked by citation-network relevance.

• loss of “sale opportunities, long term contracts, and other market advantages” are merely a reframing of economic loss”
• “[A] showing of some irreparable harm is . . . an independent prerequisite for a preliminary injunction.”
• loss in first-year sales of up to $44.55 million, or perhaps more, does not constitute irretrievable financial losses when annual revenues calculated-to be close to $7 billion
• loss of $44.55 million was “not so severe as to cause extreme hardship to [Mylan’s] business or threaten its very existence” given forecasted annual revenue of $7 billion (internal quotation marks and citation omitted)

Source: CourtListener parenthetical corpus (CC0).